Pentraxins: CRP and PTX3 and Cardiovascular Disease

Author(s): Yuichiro Maekawa, Toshiyuki Nagai, Atsushi Anzai

Journal Name: Inflammation & Allergy - Drug Targets (Discontinued)
Formerly Current Drug Targets - Inflammation & Allergy

Volume 10 , Issue 4 , 2011


The pentraxins, C-reactive protein (CRP), serum amyloid P (SAP) and pentraxin3 (PTX3) are useful biomarkers for cardiovascular disease (CVD), particularly ischemic heart disease and heart failure, and are deeply involved in the pathogenesis of CVD linked to inflammation and innate immunity. Circulating elevated pentraxins, especially CRP and PTX3 levels can provide prognostic information for a variety of clinical settings and facilitate the diagnosis of CVD. Changes in these levels over time are also important indicators of pharmacological therapy, and may indicate the mechanisms by which pentraxins directly or indirectly affect the pathophysiology of CVD in an experimental setting. Here, we discuss major relevant findings associated with the clinical implications of CRP and PTX3 and their role in CVD.

Keywords: C-reactive protein, pentraxin3, cardiovascular disease, serum amyloid P, ischemic heart disease, clinical implications of CRP, clinical implications of PTX3, myocardial infarction, myocarditis, atherosclerosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [229 - 235]
Pages: 7
DOI: 10.2174/187152811796117744
Price: $65

Article Metrics

PDF: 5